Search

Eric Arthur Vasiliauskas

from Manhattan Beach, CA
Age ~62
Get Report
Also known as:
Eric A Vasiliauskas, Eric Dr Vasiliauskas, Eric A Vasilianskas
Phone and address:
1826 5Th St, Manhattan Beach, CA 90266
(310) 376-4529
Related to:
Victor VeselkaVejas Vasiliauskas, 28Birute VeselkaVeselka Rasa, 64Rasa E Vasiliauskas, 63
Connected to:
Alex J Vasiliadis, 74Andreas N Vasiliadis, 91Bill G Vasiliadis, 61Bill T Vasili, 45Eugenia S Vasiliadis, 74Goran Vasilic, 49Ilias D Vasiliadis, 84Johanna Vasiliadis, 51Justina Vasiliauskas, 33Ljiljana J Vasilic, 43

Eric Vasiliauskas Phones & Addresses

  • 1826 5Th St, Manhattan Bch, CA 90266 (310) 376-4529 (310) 218-9729
  • 186 5Th St, Manhattan Beach, CA 90266
  • 221 33Rd St, Hermosa Beach, CA 90254 (310) 376-4529
  • Los Angeles, CA
  • Washington, DC
  • 1826 5Th St, Manhattan Beach, CA 90266

Work

Company: Inflammatory Bowel Disease Center Address: 8730 Gracie Allen Dr, Los Angeles, CA 90048 Phones: (310) 423-4100

Education

School / High School: University of Illinois At Chicago / College of Medicine 1988

Languages

English • Lithuanian

Awards

Healthgrades Honor Roll

Ranks

Certificate: Pediatrics, 2013

Specialities

Pediatrics

Professional Records

Medicine Doctors

Eric Vasiliauskas Photo 1

Dr. Eric A Vasiliauskas, Los Angeles CA - MD (Doctor of Medicine)

View page
Specialties:
Pediatrics
Address:
8700 Beverly Blvd, Los Angeles, CA 90048
(310) 967-1884 (Phone), (310) 967-1744 (Fax)

Inflammatory Bowel Disease Center
8730 Gracie Allen Dr, Los Angeles, CA 90048
(310) 423-4100 (Phone)
Certifications:
Pediatrics, 2013
Awards:
Healthgrades Honor Roll
Languages:
English
Lithuanian
Hospitals:
8700 Beverly Blvd, Los Angeles, CA 90048

Inflammatory Bowel Disease Center
8730 Gracie Allen Dr, Los Angeles, CA 90048

Cedars - Sinai Medical Center
8700 West Beverly Boulevard, West Hollywood, CA 90048
Education:
Medical School
University of Illinois At Chicago / College of Medicine
Graduated: 1988
Eric Vasiliauskas Photo 2

Eric A. Vasiliauskas

View page
Specialties:
Gastroenterology
Work:
Cedars-Sinai Medical Center Inflammatory Bowel Disease Center
8730 Alden Dr, Los Angeles, CA 90048
(310) 423-4100 (phone), (310) 423-0146 (fax)
Education:
Medical School
University of Illinois, Chicago College of Medicine
Graduated: 1988
Procedures:
Sigmoidoscopy
Conditions:
Sickle-Cell Disease
Vitamin D Deficiency
Languages:
English
Spanish
Description:
Dr. Vasiliauskas graduated from the University of Illinois, Chicago College of Medicine in 1988. He works in Los Angeles, CA and specializes in Gastroenterology. Dr. Vasiliauskas is affiliated with Cedars-Sinai Medical Center.
Eric Vasiliauskas Photo 3

Eric Arthur Vasiliauskas, Los Angeles CA

View page
Specialties:
Pediatrics
Pediatric Gastroenterology
Internal Medicine
Gastroenterology
Hematology & Oncology
Hematology
Work:
Cedars-Sinai Medical Center
8730 Alden Dr, Los Angeles, CA 90048
Education:
University of Illinois at Chicago (1988)

Publications

Us Patents

Methods Of Assessing Crohn's Disease Patient Phenotype By I2 Serologic Response

View page
US Patent:
7662569, Feb 16, 2010
Filed:
Apr 11, 2003
Appl. No.:
10/413501
Inventors:
Stephan R. Targan - Santa Monica CA, US
Eric A. Vasiliauskas - Manhattan Beach CA, US
William S. Mow - Culver City CA, US
Huiying Yang - Cerritos CA, US
Phillip R. Fleshner - Beverly Hills CA, US
Jerome I. Rotter - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
G01N 33/53
G01N 33/542
G01N 33/00
US Classification:
435 71, 435 79, 435 792
Abstract:
The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti-antibodies (ASCA), IgA anti-OmpC antibodies, or perinuclear anti-neutrophil cytoplasmic antibodies (pANCA). The methods of the invention can be used to diagnose or predict susceptibility to a clinical subtype of Crohn's disease, for example, a fibrostenotic subtype, a subtype characterized by the need for small bowel surgery, or a subtype characterized by the absence of features of ulcerative colitis.

Methods Of Assessing Crohn's Disease Patient Phenotype By I2 Serologic Response

View page
US Patent:
8163501, Apr 24, 2012
Filed:
Dec 22, 2009
Appl. No.:
12/645394
Inventors:
Stephen R. Targan - Santa Monica CA, US
Eric A. Vasiliauskas - Manhattan Beach CA, US
William S. Mow - Culver City CA, US
Huiying Yang - Cerritos CA, US
Phillip R. Fleshner - Beverly Hills CA, US
Jerome I. Rotter - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical - Los Angeles CA
International Classification:
G01N 33/53
G01N 33/542
G01N 33/00
US Classification:
435 71, 435 79, 435 792
Abstract:
The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti-antibodies (ASCA), IgA anti-OmpC antibodies, or perinuclear anti-neutrophil cytoplasmic antibodies (pANCA). The methods of the invention can be used to diagnose or predict susceptibility to a clinical subtype of Crohn's disease, for example, a fibrostenotic subtype, a subtype characterized by the need for small bowel surgery, or a subtype characterized by the absence of features of ulcerative colitis.

Methods Of Assessing Crohn's Disease Patient Phenotype By I2, Ompc And Asca Serologic Response

View page
US Patent:
20050054021, Mar 10, 2005
Filed:
Nov 26, 2003
Appl. No.:
10/723164
Inventors:
Stephan Targan - Santa Monica CA, US
Eric Vasiliauskas - Manhattan Beach CA, US
William Mow - San Ramon CA, US
Huiying Yang - Cerritos CA, US
Phillip Fleshner - Beverly Hills CA, US
Jerome Rotter - Los Angeles CA, US
International Classification:
G01N033/53
G01N033/537
G01N033/543
US Classification:
435007920
Abstract:
The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti-Saccharomyces cerevisiae antibodies (ASCA), IgA anti-OmpC antibodies, or perinuclear anti-neutrophil cytoplasmic antibodies (pANCA). The methods of the invention can be used to diagnose or predict susceptibility to a clinical subtype of Crohn's disease, for example, a fibrostenotic subtype, a subtype characterized by the need for small bowel surgery, or a subtype characterized by the absence of features of ulcerative colitis.

Methods Of Assessing Crohn's Disease Patient Phenotype By I2, Ompc And Asca Serologic Response

View page
US Patent:
20120208212, Aug 16, 2012
Filed:
Dec 6, 2011
Appl. No.:
13/312960
Inventors:
Stephan R. Targan - Santa Monica CA, US
Eric A. Vasiliauskas - Manhattan Beach CA, US
William S. Mow - San Ramon CA, US
Huiying Yang - Cerritos CA, US
Phillip R. Fleshner - Beverly Hills CA, US
Jerome I. Rotter - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
G01N 33/566
US Classification:
435 792, 436501
Abstract:
The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti-antibodies (ASCA), IgA anti-OmpC antibodies, or perinuclear anti-neutrophil cytoplasmic antibodies (pANCA). The methods of the invention can be used to diagnose or predict susceptibility to a clinical subtype of Crohn's disease, for example, a fibrostenotic subtype, a subtype characterized by the need for small bowel surgery, or a subtype characterized by the absence of features of ulcerative colitis.

Methods Of Diagnosing A Clinical Subtype Of Crohn's Disease With Features Of Ulcerative Colitis

View page
US Patent:
58742336, Feb 23, 1999
Filed:
Aug 15, 1996
Appl. No.:
8/689870
Inventors:
Stephan R. Targan - Los Angeles CA
Eric A. Vasiliauskas - Hermosa Beach CA
Scott E. Plevy - Pacific Palisades CA
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
G01N 33543
G01N 33564
US Classification:
435 724
Abstract:
The present invention provides a method of diagnosing a clinical subtype of Crohn's disease (CD) by determining whether perinuclear anti-neutrophil antibodies (pANCA) are present in a patient with CD, where the presence of pANCA indicates the clinical subtype of CD with features of ulcerative colitis (UC). The invention also provides a method of diagnosing a clinical subtype of CD by detecting an Arg. sup. 241 allele at an ICAM-1 locus in a patient with CD, where the Arg. sup. 241 allele indicates a clinical subtype of CD with features of ulcerative colitis. In addition, the invention provides a method of diagnosing a pANCA-positive subtype of CD by detecting an Arg. sup. 241 allele at an ICAM-1 locus in a patient with CD, where the Arg. sup. 241 allele indicates the pANCA-positive subtype of CD.

Methods Of Diagnosing Clinical Subtypes Of Crohn's Disease

View page
US Patent:
59324295, Aug 3, 1999
Filed:
Apr 11, 1997
Appl. No.:
8/837059
Inventors:
Stephan R. Targan - Santa Monica CA
Eric A. Vasiliauskas - Hermosa Beach CA
Scott E. Plevy - Tenafly NJ
Mary J. Barry - Ramona CA
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
Prometheus Laboratories Inc. - San Diego CA
International Classification:
G01N 33564
US Classification:
435 724
Abstract:
Provided herein is a method of diagnosing a clinical subtype of Crohn's disease (CD) by determining whether perinuclear anti-neutrophil antibody (pANCA) is present in a patient with CD, where the presence of pANCA indicates a clinical subtype of CD with features of ulcerative colitis (UC). Also provided is a method of diagnosing a clinical subtype of Crohn's disease in a patient with CD by determining whether pANCA or speckling anti-pan polymorphonuclear antibody (SAPPA) is present in the patient with CD, where the presence of pANCA indicates a clinical subtype of CD with features of ulcerative colitis and where the presence of SAPPA indicates a clinical subtype of CD having perforating, fistulizing or small bowel obstructive disease. The invention further provides a method of diagnosing a clinical subtype of Crohn's disease in a patient with CD by determining the presence or absence of ANCA, pANCA, SAPPA and anti-Saccharomyces cerevisiae antibodies (ASCA) in the patient with CD, where the presence of pANCA combined with the absence of ASCA indicate a clinical subtype of CD with features of UC, the presence of SAPPA indicates a clinical subtype of CD having perforating or fistulizing disease or small bowel obstructive disease, and the presence of ASCA combined with the absence of ANCA indicates a clinical subtype of CD lacking features of ulcerative colitis and having perforating or fistulizing disease or small bowel obstructive disease. Kits for diagnosing a clinical subtype of Crohn's disease, which contain neutrophil and antigen specific for ASCA, also are provided.

Method Of Diagnosing A Clinical Subtype Of Crohn's Disease With Features Of Ulcerative Colitis

View page
US Patent:
59167483, Jun 29, 1999
Filed:
Aug 15, 1996
Appl. No.:
8/689873
Inventors:
Stephan R. Targan - Santa Monica CA
Eric A. Vasiliauskas - Hermosa Beach CA
Scott E. Plevy - Tenafly NJ
Huiying Yang - Cerritos CA
Jerome I. Rotter - Los Angeles CA
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
C12Q 168
G01N 33564
US Classification:
435 6
Abstract:
The present invention provides a method of diagnosing a clinical subtype of Crohn's disease (CD) by determining whether perinuclear anti-neutrophil antibodies (pANCA) are present in a patient with CD, where the presence of pANCA indicates the clinical subtype of CD with features of ulcerative colitis (UC). The invention also provides a method of diagnosing a clinical subtype of CD by detecting an Arg. sup. 241 allele at an ICAM-1 locus in a patient with CD, where the Arg. sup. 241 allele indicates a clinical subtype of CD with features of ulcerative colitis. In addition, the invention provides a method of diagnosing a pANCA-positive subtype of CD by detecting an Arg. sup. 241 allele at an ICAM-1 locus in a patient with CD, where the Arg. sup. 241 allele indicates the pANCA-positive subtype of CD.
Control profile
Eric Arthur Vasiliauskas from Manhattan Beach, CA, age ~62 Get Report